EF Hutton Maintains Buy on UroGen Pharma, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for UroGen Pharma (NASDAQ:URGN) and maintained a price target of $25.
October 21, 2024 | 11:26 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
EF Hutton analyst Jason Kolbert has reiterated a Buy rating for UroGen Pharma and maintained a price target of $25, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $25 price target by EF Hutton suggests a positive outlook for UroGen Pharma. This could lead to increased investor confidence and potentially a short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100